Stock Screener · Library
Nuvectis Pharma, Inc. financial statement history
Source-linked financial facts for Nuvectis Pharma, Inc. with exact reported periods, units and filing dates. Historical periods ending 2021–2025.
What this record covers
This historical reference uses a locally cached SEC companyfacts snapshot and reports periods ending from 2021 through 2025. It is not a current quotation feed, a screening recommendation or a verification of the company's present condition.
Each value retains its reported unit and exact period. Filing fiscal year describes the submitting filing and can differ from the year of a comparative fact. Values with different currencies or period boundaries are not combined.
Total assets
| Reported period | Value | Unit | Filed | Filing FY / FP | Taxonomy concept | Source filing |
|---|---|---|---|---|---|---|
| As of 2021-12-31 | 6657000 | USD | 2023-03-08 | 2022 / FY | us-gaap:Assets | 10-K · 0001558370-23-003181 |
| As of 2022-12-31 | 20405000 | USD | 2024-03-05 | 2023 / FY | us-gaap:Assets | 10-K · 0001558370-24-002497 |
| As of 2023-12-31 | 19185000 | USD | 2025-02-25 | 2024 / FY | us-gaap:Assets | 10-K · 0001558370-25-001496 |
| As of 2024-12-31 | 18607000 | USD | 2026-02-11 | 2025 / FY | us-gaap:Assets | 10-K · 0001104659-26-013044 |
| As of 2025-12-31 | 31709000 | USD | 2026-02-11 | 2025 / FY | us-gaap:Assets | 10-K · 0001104659-26-013044 |
Current assets
| Reported period | Value | Unit | Filed | Filing FY / FP | Taxonomy concept | Source filing |
|---|---|---|---|---|---|---|
| As of 2021-12-31 | 5833000 | USD | 2023-03-08 | 2022 / FY | us-gaap:AssetsCurrent | 10-K · 0001558370-23-003181 |
| As of 2022-12-31 | 20405000 | USD | 2024-03-05 | 2023 / FY | us-gaap:AssetsCurrent | 10-K · 0001558370-24-002497 |
| As of 2023-12-31 | 19185000 | USD | 2025-02-25 | 2024 / FY | us-gaap:AssetsCurrent | 10-K · 0001558370-25-001496 |
| As of 2024-12-31 | 18607000 | USD | 2026-02-11 | 2025 / FY | us-gaap:AssetsCurrent | 10-K · 0001104659-26-013044 |
| As of 2025-12-31 | 31709000 | USD | 2026-02-11 | 2025 / FY | us-gaap:AssetsCurrent | 10-K · 0001104659-26-013044 |
Cash and cash equivalents
| Reported period | Value | Unit | Filed | Filing FY / FP | Taxonomy concept | Source filing |
|---|---|---|---|---|---|---|
| As of 2021-12-31 | 5742000 | USD | 2023-03-08 | 2022 / FY | us-gaap:CashAndCashEquivalentsAtCarryingValue | 10-K · 0001558370-23-003181 |
| As of 2022-12-31 | 19993000 | USD | 2024-03-05 | 2023 / FY | us-gaap:CashAndCashEquivalentsAtCarryingValue | 10-K · 0001558370-24-002497 |
| As of 2023-12-31 | 19126000 | USD | 2025-02-25 | 2024 / FY | us-gaap:CashAndCashEquivalentsAtCarryingValue | 10-K · 0001558370-25-001496 |
| As of 2024-12-31 | 18533000 | USD | 2026-02-11 | 2025 / FY | us-gaap:CashAndCashEquivalentsAtCarryingValue | 10-K · 0001104659-26-013044 |
| As of 2025-12-31 | 31634000 | USD | 2026-02-11 | 2025 / FY | us-gaap:CashAndCashEquivalentsAtCarryingValue | 10-K · 0001104659-26-013044 |
Total liabilities
| Reported period | Value | Unit | Filed | Filing FY / FP | Taxonomy concept | Source filing |
|---|---|---|---|---|---|---|
| As of 2021-12-31 | 2419000 | USD | 2023-03-08 | 2022 / FY | us-gaap:Liabilities | 10-K · 0001558370-23-003181 |
| As of 2022-12-31 | 6186000 | USD | 2024-03-05 | 2023 / FY | us-gaap:Liabilities | 10-K · 0001558370-24-002497 |
| As of 2023-12-31 | 6984000 | USD | 2025-02-25 | 2024 / FY | us-gaap:Liabilities | 10-K · 0001558370-25-001496 |
| As of 2024-12-31 | 8894000 | USD | 2026-02-11 | 2025 / FY | us-gaap:Liabilities | 10-K · 0001104659-26-013044 |
| As of 2025-12-31 | 13296000 | USD | 2026-02-11 | 2025 / FY | us-gaap:Liabilities | 10-K · 0001104659-26-013044 |
Current liabilities
| Reported period | Value | Unit | Filed | Filing FY / FP | Taxonomy concept | Source filing |
|---|---|---|---|---|---|---|
| As of 2021-12-31 | 2419000 | USD | 2023-03-08 | 2022 / FY | us-gaap:LiabilitiesCurrent | 10-K · 0001558370-23-003181 |
| As of 2022-12-31 | 6186000 | USD | 2024-03-05 | 2023 / FY | us-gaap:LiabilitiesCurrent | 10-K · 0001558370-24-002497 |
| As of 2023-12-31 | 6984000 | USD | 2025-02-25 | 2024 / FY | us-gaap:LiabilitiesCurrent | 10-K · 0001558370-25-001496 |
| As of 2024-12-31 | 8894000 | USD | 2026-02-11 | 2025 / FY | us-gaap:LiabilitiesCurrent | 10-K · 0001104659-26-013044 |
| As of 2025-12-31 | 13296000 | USD | 2026-02-11 | 2025 / FY | us-gaap:LiabilitiesCurrent | 10-K · 0001104659-26-013044 |
Stockholders equity
| Reported period | Value | Unit | Filed | Filing FY / FP | Taxonomy concept | Source filing |
|---|---|---|---|---|---|---|
| As of 2021-12-31 | -11008000 | USD | 2024-03-05 | 2023 / FY | us-gaap:StockholdersEquity | 10-K · 0001558370-24-002497 |
| As of 2022-12-31 | 14219000 | USD | 2025-02-25 | 2024 / FY | us-gaap:StockholdersEquity | 10-K · 0001558370-25-001496 |
| As of 2023-12-31 | 12201000 | USD | 2026-02-11 | 2025 / FY | us-gaap:StockholdersEquity | 10-K · 0001104659-26-013044 |
| As of 2024-12-31 | 9713000 | USD | 2026-02-11 | 2025 / FY | us-gaap:StockholdersEquity | 10-K · 0001104659-26-013044 |
| As of 2025-12-31 | 18413000 | USD | 2026-02-11 | 2025 / FY | us-gaap:StockholdersEquity | 10-K · 0001104659-26-013044 |
Research and development
| Reported period | Value | Unit | Filed | Filing FY / FP | Taxonomy concept | Source filing |
|---|---|---|---|---|---|---|
| 2021-01-01 to 2021-12-31 | 9545000 | USD | 2023-03-08 | 2022 / FY | us-gaap:ResearchAndDevelopmentExpense | 10-K · 0001558370-23-003181 |
| 2022-01-01 to 2022-12-31 | 13227000 | USD | 2024-03-05 | 2023 / FY | us-gaap:ResearchAndDevelopmentExpense | 10-K · 0001558370-24-002497 |
| 2023-01-01 to 2023-12-31 | 15380000 | USD | 2025-02-25 | 2024 / FY | us-gaap:ResearchAndDevelopmentExpense | 10-K · 0001558370-25-001496 |
| 2024-01-01 to 2024-12-31 | 12918000 | USD | 2026-02-11 | 2025 / FY | us-gaap:ResearchAndDevelopmentExpense | 10-K · 0001104659-26-013044 |
| 2025-01-01 to 2025-12-31 | 18153000 | USD | 2026-02-11 | 2025 / FY | us-gaap:ResearchAndDevelopmentExpense | 10-K · 0001104659-26-013044 |
Operating income
| Reported period | Value | Unit | Filed | Filing FY / FP | Taxonomy concept | Source filing |
|---|---|---|---|---|---|---|
| 2021-01-01 to 2021-12-31 | -12894000 | USD | 2023-03-08 | 2022 / FY | us-gaap:OperatingIncomeLoss | 10-K · 0001558370-23-003181 |
| 2022-01-01 to 2022-12-31 | -19234000 | USD | 2024-03-05 | 2023 / FY | us-gaap:OperatingIncomeLoss | 10-K · 0001558370-24-002497 |
| 2023-01-01 to 2023-12-31 | -22897000 | USD | 2025-02-25 | 2024 / FY | us-gaap:OperatingIncomeLoss | 10-K · 0001558370-25-001496 |
| 2024-01-01 to 2024-12-31 | -19847000 | USD | 2026-02-11 | 2025 / FY | us-gaap:OperatingIncomeLoss | 10-K · 0001104659-26-013044 |
| 2025-01-01 to 2025-12-31 | -27574000 | USD | 2026-02-11 | 2025 / FY | us-gaap:OperatingIncomeLoss | 10-K · 0001104659-26-013044 |
Net income
| Reported period | Value | Unit | Filed | Filing FY / FP | Taxonomy concept | Source filing |
|---|---|---|---|---|---|---|
| 2021-01-01 to 2021-12-31 | -12890000 | USD | 2023-03-08 | 2022 / FY | us-gaap:NetIncomeLoss | 10-K · 0001558370-23-003181 |
| 2022-01-01 to 2022-12-31 | -19085000 | USD | 2024-03-05 | 2023 / FY | us-gaap:NetIncomeLoss | 10-K · 0001558370-24-002497 |
| 2023-01-01 to 2023-12-31 | -22260000 | USD | 2025-02-25 | 2024 / FY | us-gaap:NetIncomeLoss | 10-K · 0001558370-25-001496 |
| 2024-01-01 to 2024-12-31 | -19000000 | USD | 2026-02-11 | 2025 / FY | us-gaap:NetIncomeLoss | 10-K · 0001104659-26-013044 |
| 2025-01-01 to 2025-12-31 | -26442000 | USD | 2026-02-11 | 2025 / FY | us-gaap:NetIncomeLoss | 10-K · 0001104659-26-013044 |
Diluted earnings per share
| Reported period | Value | Unit | Filed | Filing FY / FP | Taxonomy concept | Source filing |
|---|---|---|---|---|---|---|
| 2021-01-01 to 2021-12-31 | -3.02 | USD/shares | 2023-03-08 | 2022 / FY | us-gaap:EarningsPerShareDiluted | 10-K · 0001558370-23-003181 |
| 2022-01-01 to 2022-12-31 | -1.51 | USD/shares | 2024-03-05 | 2023 / FY | us-gaap:EarningsPerShareDiluted | 10-K · 0001558370-24-002497 |
| 2023-01-01 to 2023-12-31 | -1.43 | USD/shares | 2025-02-25 | 2024 / FY | us-gaap:EarningsPerShareDiluted | 10-K · 0001558370-25-001496 |
| 2024-01-01 to 2024-12-31 | -1.11 | USD/shares | 2026-02-11 | 2025 / FY | us-gaap:EarningsPerShareDiluted | 10-K · 0001104659-26-013044 |
| 2025-01-01 to 2025-12-31 | -1.32 | USD/shares | 2026-02-11 | 2025 / FY | us-gaap:EarningsPerShareDiluted | 10-K · 0001104659-26-013044 |
Operating cash flow
| Reported period | Value | Unit | Filed | Filing FY / FP | Taxonomy concept | Source filing |
|---|---|---|---|---|---|---|
| 2021-01-01 to 2021-12-31 | -9504000 | USD | 2023-03-08 | 2022 / FY | us-gaap:NetCashProvidedByUsedInOperatingActivities | 10-K · 0001558370-23-003181 |
| 2022-01-01 to 2022-12-31 | -13559000 | USD | 2024-03-05 | 2023 / FY | us-gaap:NetCashProvidedByUsedInOperatingActivities | 10-K · 0001558370-24-002497 |
| 2023-01-01 to 2023-12-31 | -15954000 | USD | 2025-02-25 | 2024 / FY | us-gaap:NetCashProvidedByUsedInOperatingActivities | 10-K · 0001558370-25-001496 |
| 2024-01-01 to 2024-12-31 | -12247000 | USD | 2026-02-11 | 2025 / FY | us-gaap:NetCashProvidedByUsedInOperatingActivities | 10-K · 0001104659-26-013044 |
| 2025-01-01 to 2025-12-31 | -16009000 | USD | 2026-02-11 | 2025 / FY | us-gaap:NetCashProvidedByUsedInOperatingActivities | 10-K · 0001104659-26-013044 |
Source and method
SEC public numeric facts are reorganized into a standard reference. Tag priority follows the native app's declared concept chains; the latest filed observation is selected within the same exact start, end and unit. A missing value stays missing. No currency, quarterly total, ratio, share-price series or dividend calendar is inferred.
The ticker below belongs to the native source snapshot. Company names, tickers and reporting structures may change; CIK identifies the source filer.
- Source filer CIK
- 1875558
- Ticker in native snapshot
- NVCT
- Reported numeric facts
- 55
- Units present
- USD · USD/shares